A Phase 2 interventional study of Dronabinol and Placebo in Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting and HIV Infections, sponsored by Solvay Pharmaceuticals. Completed at 36 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-04-02.
Sponsored by Solvay Pharmaceuticals (part of Abbott) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 286 studies in Vomiting with a site in United States — 26 open to participants now, 29 under way, 5 of them phase 3. Vomiting · United States.
Among the 286 studies in Vomiting with a site in United States, this one is the 111th largest by enrollment of the 256 interventional ones that give a count, is one of 9 that started in 2003, is one of 57 in phase 2, and was the 68th registered.
794 studies on the registry are indexed under Vomiting; 99 are open to participants now.
Browse Vomiting studies →26 of the 286 studies in Vomiting with a site in United States are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States
Ages 18–65 · Healthy volunteers
University of Southern California · Sites in United States
Ages 18–49 · Women only · Healthy volunteers
Vanda Pharmaceuticals · Sites in United States
Ages 18–65 · Healthy volunteers
David Levinthal · Sites in United States
Ages 21–60 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Australia, China and 7 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
286 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 68 · Phase 3 54 · Phase 4 34
First in 1999; this study’s year is marked. 9 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is close to the median of 103 across 674 interventional studies indexed under Vomiting.
Median enrollment 89 across the 256 interventional studies, 64 across the 25 observational. Of the 230 that completed or were terminated, 121 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 286 have an industry lead sponsor. The 10 most frequent:
This study is registered under Solvay Pharmaceuticals, one of the names counted as Abbott. Under that name alone:
Solvay Pharmaceuticals is the lead sponsor of 86 studies on the registry; none are open to participants now.
Abbott has 3 studies filed under Vomiting — fewer than ten, so there is no comparison to draw.
15 of the studies in Vomiting with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07446439Phase 3Vanda PharmaceuticalsA Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | 2026-12-01 |
| NCT06382012Phase 3Montefiore Medical CenterAntiemetic Fosaprepitant To Remedy Nausea and Vomiting | 2027-03 |
| NCT05418244Phase 3State University of New York at BuffaloInhaled Isopropyl Alcohol for Treatment of Nausea | 2027-06-30 |
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
Add all 15 to your calendar (.ics) → With an account.
Among the 286 studies in Vomiting with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dronabinol
Drug: Placebo
2.5 mg to 40 mg
placebo
The absence of nausea as indicated by a visual analog scale (VAS) score < 5 mm
Time frame: 2 weeks
Number of episodes vomiting/retching
Time frame: 2 weeks
Duration of nausea, vomiting/retching
Time frame: 2 weeks
Intensity of nausea by VAS
Time frame: 2 weeks
Appetite stimulation by VAS
Time frame: 2 weeks
The record gives a start of Aug 2003, a primary completion of Apr 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronabinol